GANX

Gain Therapeutics, Inc. [GANX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

GANX Stock Summary

Top 10 Correlated ETFs

GANX


Top 10 Correlated Stocks

GANX


In the News

01:32 10 Dec 2023 GANX

Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock

Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.

08:45 10 Dec 2023 GANX

Why Is Gain Therapeutics (GANX) Stock Moving Today?

Gain Therapeutics (NASDAQ: GANX ) stock is on the move Wednesday as investors react to updated clinical trial news from the company. According to a press release from Gain Therapeutics, the company has started dosing the first two subjects in its Phase 1 clinical trial.

04:05 10 Dec 2023 GANX

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's Chief Executive Officer, Matthias Alder, will participate in a fireside chat and host one-on-one meetings at Cantor Fitzgerald Global Healthcare Conference taking place in New York, NY, September 26-28, 2023.

04:05 10 Dec 2023 GANX

Gain Therapeutics to Present at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets Conference

BETHESDA, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer of Gain Therapeutics, will deliver a featured presentation at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets Conference: Drug Discovery for Progressive Central Nervous System Disorders. The event is taking place at the Sheraton Boston in Boston, Massachusetts, between September 26-27, 2023.

10:01 10 Dec 2023 GANX

Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Misses Revenue Estimates

Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.43 per share a year ago.

08:00 10 Dec 2023 GANX

Gain Therapeutics to Present at the Jefferies Healthcare Conference

BETHESDA, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will present at the Jefferies Healthcare Conference, taking place June 7-9 in New York, NY.

10:39 10 Dec 2023 GANX

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates

Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.28 per share a year ago.

08:52 10 Dec 2023 GANX

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer's disease Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer's disease

04:05 10 Dec 2023 GANX

Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference

BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, CEO, will present a corporate update at the Sidoti Small-Cap Virtual Investor Conference on Wednesday, January 18 at 2:30 PM ET.

06:48 10 Dec 2023 GANX

Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

GANX Financial details

Company Rating
Neutral
Market Cap
41.14M
Income
-22.22M
Revenue
195.29K
Book val./share
0.58
Cash/share
0.96
Dividend
-
Dividend %
-
Employees
28
Optionable
No
Shortable
Yes
Earnings
14 Nov 2023
P/E
-1.55
Forward P/E
-1.94
PEG
-0.48
P/S
210.64
P/B
4.71
P/C
2.83
P/FCF
-2.4
Quick Ratio
2.14
Current Ratio
2.3
Debt / Equity
0.14
LT Debt / Equity
0.1
-
-
EPS (TTM)
-1.81
EPS next Y
-1.4
EPS next Q
-0.34
EPS this Y
8.03%
EPS next Y
-22.65%
EPS next 5Y
-12.15%
EPS last 5Y
50.77%
Revenue last 5Y
46.72%
Revenue Q/Q
-
EPS Q/Q
-40.32%
-
-
-
-
SMA20
-15.11%
SMA50
-28.05%
SMA100
-47.56%
Inst Own
4.8%
Inst Trans
0.48%
ROA
-158%
ROE
-169%
ROC
-2.69%
Gross Margin
100%
Oper. Margin
-11474%
Profit Margin
-11377%
Payout
-
Shs Outstand
15.12M
Shs Float
12.01M
-
-
-
-
Target Price
7
52W Range
2.0-6.19
52W High
-54.67%
52W Low
+36%
RSI
56.45
Rel Volume
3.35
Avg Volume
58.25K
Volume
195.39K
Perf Week
21.97%
Perf Month
-7.33%
Perf Quarter
-44.03%
Perf Half Y
-43.92%
-
-
-
-
Beta
0.122
-
-
Volatility
0.18%, 0.28%
Prev Close
7.94%
Price
2.72
Change
11.48%

GANX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.010.010.020.01
Net income per share
-0.19-0.37-1.33-1.37-1.48
Operating cash flow per share
-0.13-0.32-1.21-1.22-1.24
Free cash flow per share
-0.13-0.32-1.22-1.23-1.25
Cash per share
00.052.793.631.69
Book value per share
0-0.082.313.431.59
Tangible book value per share
0-0.082.313.411.57
Share holders equity per share
0-0.082.313.431.59
Interest debt per share
00.030.470.160.09
Market cap
65.63M65.63M30.03M55.2M37.19M
Enterprise value
065.53M23.8M19.93M31.16M
P/E ratio
-59.37-29.92-8.39-3.97-2.11
Price to sales ratio
3.18K1.59K1.04K334.55265.47
POCF ratio
-88.16-35.13-9.27-4.46-2.53
PFCF ratio
-87.22-34.87-9.21-4.43-2.51
P/B Ratio
0-145.94.841.591.97
PTB ratio
0-145.94.841.591.97
EV to sales
01.59K824.08120.77222.38
Enterprise value over EBITDA
0-32.25-7.06-1.45-1.76
EV to operating cash flow
0-35.07-7.35-1.61-2.12
EV to free cash flow
0-34.82-7.3-1.6-2.1
Earnings yield
-0.02-0.03-0.12-0.25-0.47
Free cash flow yield
-0.01-0.03-0.11-0.23-0.4
Debt to equity
0-0.450.20.050.07
Debt to assets
00.30.130.040.05
Net debt to EBITDA
00.051.852.560.34
Current ratio
00.494.2514.785.11
Interest coverage
000071.86
Income quality
0.670.850.910.890.84
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
10.7713.4443.2541.3868.09
Research and developement to revenue
40.1238.4178.2243.4259.79
Intangibles to total assets
0000.010.01
Capex to operating cash flow
0.010.010.010.010.01
Capex to revenue
-0.39-0.33-0.72-0.57-0.85
Capex to depreciation
-10.78-5.34-2.17-6.08-1.85
Stock based compensation to revenue
002.835.0910.89
Graham number
00.88.3310.267.27
ROIC
043.93-0.44-0.37-0.86
Return on tangible assets
0-3.32-0.37-0.36-0.74
Graham Net
0-0.131.543.231.26
Working capital
0-449.53K6.87M35.17M16.97M
Tangible asset value
0-449.86K6.2M34.61M18.67M
Net current asset value
0-680.62K5.59M33.55M15.87M
Invested capital
0-0.450.20.050.07
Average receivables
0055.74K90.08K108.73K
Average payables
00557.98K761K1.09M
Average inventory
00000
Days sales outstanding
0396.94841.25251.28270.61
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00.920.431.451.35
Payables turnover
00000
Inventory turnover
00000
ROE
04.88-0.58-0.4-0.93
Capex per share
00-0.01-0.01-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.01000
Net income per share
-0.38-0.39-0.43-0.62-0.37
Operating cash flow per share
-0.28-0.33-0.35-0.41-0.31
Free cash flow per share
-0.28-0.33-0.35-0.41-0.31
Cash per share
1.911.691.491.310.96
Book value per share
1.911.591.270.90.58
Tangible book value per share
1.891.571.250.880.56
Share holders equity per share
1.911.591.270.90.58
Interest debt per share
0.120.090.110.090.08
Market cap
38.74M37.19M57.53M55.49M41.66M
Enterprise value
29.13M31.16M52.74M50.32M38.43M
P/E ratio
-2.12-1.99-2.8-1.8-2.21
Price to sales ratio
0265.471.04K00
POCF ratio
-11.78-9.53-13.64-11.05-10.5
PFCF ratio
-11.58-9.5-13.6-11.04-10.5
P/B Ratio
1.711.973.855.68
PTB ratio
1.711.973.855.68
EV to sales
0222.38955.8700
Enterprise value over EBITDA
-6.1-7.17-10.17-6.58-7.74
EV to operating cash flow
-8.86-7.98-12.51-10.02-9.69
EV to free cash flow
-8.7-7.96-12.47-10.01-9.69
Earnings yield
-0.12-0.13-0.09-0.14-0.11
Free cash flow yield
-0.09-0.11-0.07-0.09-0.1
Debt to equity
0.060.070.080.10.14
Debt to assets
0.040.050.060.060.07
Net debt to EBITDA
2.011.390.920.680.65
Current ratio
5.625.113.753.12.3
Interest coverage
-30.9821.56-34.400
Income quality
0.720.840.820.650.84
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
016.3345.1900
Research and developement to revenue
016.2350.5800
Intangibles to total assets
0.010.010.010.010.01
Capex to operating cash flow
0.020000
Capex to revenue
0-0.07-0.200
Capex to depreciation
-3.21-0.52-0.57-0.18-0.03
Stock based compensation to revenue
03.9910.2500
Graham number
4.063.753.53.542.2
ROIC
-0.19-0.22-0.31-0.61-0.55
Return on tangible assets
-0.16-0.2-0.24-0.43-0.34
Graham Net
1.451.260.980.730.44
Working capital
20.02M16.97M14.17M11.72M7.48M
Tangible asset value
22.45M18.67M14.93M10.89M7.14M
Net current asset value
18.69M15.87M13.14M10.14M6.47M
Invested capital
0.060.070.080.10.14
Average receivables
149.98K179.85K164.35K149.06K131.32K
Average payables
983.86K1.32M1.92M1.57M1.15M
Average inventory
0-95.65K-95.65K-80.37K-80.37K
Days sales outstanding
0122.89224.0800
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00.730.400
Payables turnover
00000
Inventory turnover
00000
ROE
-0.2-0.25-0.34-0.69-0.64
Capex per share
00000

GANX Frequently Asked Questions

What is Gain Therapeutics, Inc. stock symbol ?

Gain Therapeutics, Inc. is a US stock , located in Bethesda of Md and trading under the symbol GANX

Is Gain Therapeutics, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $7. The lowest prediction is $4 and the highest is $10

What is GANX stock prediction ?

What is Gain Therapeutics, Inc. stock quote today ?

Gain Therapeutics, Inc. stock price is $2.72 today.

Is Gain Therapeutics, Inc. stock public?

Yes, Gain Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap